Covishield up to eight weeks after the first shot from up to six weeks earlier. The increase in interval was only allowed for Covishield, a version of the vaccine co-developed by AstraZeneca and University of Oxford, and not for Bharat Biotech International’s Covaxin.
Mint delves into why it was done and what could be the potential impact of the change in interval.Why did the government decide to increase the dosing interval for Covishield?The government’s decision was based on recommendation for the change from the National Technical Advisory Group on Immunisation (NTAGI) and subsequently the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).